Myogen Inc.

Mr. Van Dusen has served as Vice President of Business Development of Myogen since October 1998. From September 1997 to October 1998, Mr. Van Dusen was Vice President, Business Development of RxKinetix, Inc., a drug delivery company. From January 1995 to August 1997, he served as a marketing and business development consultant to the biotechnology industry. From April 1992 to December 1994, Mr. Van Dusen served as Manager of Corporate Development and Planning for Somatogen, Inc., a company developing recombinant therapeutics for oxygen delivery. Previously, Mr. Van Dusen spent seven years with Baxter Healthcare where he held a variety of marketing and business development positions. Mr. Van Dusen holds a B.S.E. from Duke University, an M.S. in bioengineering from the University of Michigan and an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management.

Dr. Oronsky has been a member of our Board of Directors since November 1996 and was elected Chairman in February 2006. Dr. Oronsky is a general partner with InterWest Partners, a venture capital firm. Prior to joining InterWest Partners in 1994, Dr. Oronsky was vice president of discovery research for the Lederle Laboratories division of American Cyanamid, a pharmaceutical company. From 1973 until 1976, Dr. Oronsky was head of the inflammation, allergy and immunology research program at Ciba-Geigy Pharmaceutical Company. Dr. Oronsky also serves as a senior lecturer in the Department of Medicine at Johns Hopkins Medical School. Dr. Oronsky has won numerous grants and awards and has published over 125 scientific articles. Dr. Oronsky serves on the boards of directors of Aspreva Pharmaceuticals Corporation; Anesiva, Inc.; and Metabasis Therapeutics, Inc. He received his Ph.D. from Columbia University, College of Physicians and Surgeons, and his AB from New York University.